Skip to content
The Nexus
DossierENTITY

Attovia Therapeutics Inc.

Coverage of Attovia Therapeutics Inc. in the Nexus archive.

Earliest in view: Aug 5 · 01:06 UTCMost recent: Aug 5 · 01:06 UTC
Co-mentioned in this coverage
Goldman Sachsorganization1immune system diseasestopic1initial public offeringtopic1
Recent coverage
  • BUSINESSAug 5 · 01:06 UTCBLOOMBERG
    Goldman-Backed Biotech Attovia Raises $289 Million in US IPO

    Attovia Therapeutics Inc., a biotech firm developing treatments for immune system diseases with high unmet need, raised $289 million in a US initial public offering that priced at the top of its marketed range. Goldman Sachs backed the company during its IPO.

Attovia Therapeutics Inc. · Dossier · The Nexus